333 related articles for article (PubMed ID: 18691115)
1. Targeting cyclooxygenase-2 in hematological malignancies: rationale and promise.
Bernard MP; Bancos S; Sime PJ; Phipps RP
Curr Pharm Des; 2008; 14(21):2051-60. PubMed ID: 18691115
[TBL] [Abstract][Full Text] [Related]
2. The cyclooxygenase-2/prostaglandin E
Zmigrodzka M; Rzepecka A; Krzyzowska M; Witkowska-Pilaszewicz O; Cywinska A; Winnicka A
J Physiol Pharmacol; 2018 Oct; 69(5):. PubMed ID: 30683818
[TBL] [Abstract][Full Text] [Related]
3. Biology of Cox-2: an application in cancer therapeutics.
Khan Z; Khan N; Tiwari RP; Sah NK; Prasad GB; Bisen PS
Curr Drug Targets; 2011 Jun; 12(7):1082-93. PubMed ID: 21443470
[TBL] [Abstract][Full Text] [Related]
4. In vitro and in vivo inhibitory effect evaluation of cyclooxygenase-2 inhibitors, antisense cyclooxygenase-2 cDNA, and their combination on the growth of human bladder cancer cells.
Qin J; Yuan J; Li L; Liu H; Qin R; Qin W; Chen B; Wang H; Wu K
Biomed Pharmacother; 2009 Mar; 63(3):241-8. PubMed ID: 18617357
[TBL] [Abstract][Full Text] [Related]
5. [Lenalidomide in hematological malignancies---review].
Jin X; Zhang YZ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Feb; 20(1):205-9. PubMed ID: 22391198
[TBL] [Abstract][Full Text] [Related]
6. Targeting immune checkpoints in hematological malignancies.
Salik B; Smyth MJ; Nakamura K
J Hematol Oncol; 2020 Aug; 13(1):111. PubMed ID: 32787882
[TBL] [Abstract][Full Text] [Related]
7. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
Plosker GL; Figgitt DP
Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
[TBL] [Abstract][Full Text] [Related]
8. Eicosanoid modulation in advanced lung cancer: cyclooxygenase-2 expression is a positive predictive factor for celecoxib + chemotherapy--Cancer and Leukemia Group B Trial 30203.
Edelman MJ; Watson D; Wang X; Morrison C; Kratzke RA; Jewell S; Hodgson L; Mauer AM; Gajra A; Masters GA; Bedor M; Vokes EE; Green MJ
J Clin Oncol; 2008 Feb; 26(6):848-55. PubMed ID: 18281656
[TBL] [Abstract][Full Text] [Related]
9. Combined chemotherapy with cyclooxygenase-2 (COX-2) inhibitors in treating human cancers: Recent advancement.
Li S; Jiang M; Wang L; Yu S
Biomed Pharmacother; 2020 Sep; 129():110389. PubMed ID: 32540642
[TBL] [Abstract][Full Text] [Related]
10. The prognostic and therapeutic potentials of CTLA-4 in hematological malignancies.
Sadeghi M; Khodakarami A; Ahmadi A; Fathi M; Gholizadeh Navashenaq J; Mohammadi H; Yousefi M; Hojjat-Farsangi M; Movasaghpour Akbari AA; Jadidi-Niaragh F
Expert Opin Ther Targets; 2022 Dec; 26(12):1057-1071. PubMed ID: 36683579
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic potential of selective cyclooxygenase-2 inhibitors in the management of tumor angiogenesis.
Gately S; Kerbel R
Prog Exp Tumor Res; 2003; 37():179-92. PubMed ID: 12795055
[TBL] [Abstract][Full Text] [Related]
12. Myeloid-derived suppressor cells in hematological malignancies: friends or foes.
Lv M; Wang K; Huang XJ
J Hematol Oncol; 2019 Oct; 12(1):105. PubMed ID: 31640764
[TBL] [Abstract][Full Text] [Related]
13. Phase I/II trial of cure-oriented high-dose chemoradiotherapy with transplantation of CD34+ peripheral blood stem cells purified by the immunomagnetic bead method for refractory hematological malignancies. Nagoya CD34+ PBSCT Study Group.
Ogura M; Kagami Y; Suzuki R; Miura K; Uehira K; Kurokawa T; Ito T; Kinoshita T; Emi N; Morishima Y; Kodera Y; Ueda R
Cancer Chemother Pharmacol; 1997; 40 Suppl():S51-7. PubMed ID: 9272135
[TBL] [Abstract][Full Text] [Related]
14. Identification of novel COX-2 / CYP19A1 axis involved in the mesothelioma pathogenesis opens new therapeutic opportunities.
Nuvoli B; Antoniani B; Libener R; Maconi A; Sacconi A; Carosi M; Galati R
J Exp Clin Cancer Res; 2021 Aug; 40(1):257. PubMed ID: 34404424
[TBL] [Abstract][Full Text] [Related]
15. SLAMF1/CD150 in hematologic malignancies: Silent marker or active player?
Gordiienko I; Shlapatska L; Kovalevska L; Sidorenko SP
Clin Immunol; 2019 Jul; 204():14-22. PubMed ID: 30616923
[TBL] [Abstract][Full Text] [Related]
16. The search for new COX-2 inhibitors: a review of 2002 - 2008 patents.
Ramalho TC; Rocha M; da Cunha EF; Freitas MP
Expert Opin Ther Pat; 2009 Sep; 19(9):1193-228. PubMed ID: 19563267
[TBL] [Abstract][Full Text] [Related]
17. Expression patterns of costimulatory molecules on cells derived from human hematological malignancies.
Zheng Z; Takahashi M; Aoki S; Toba K; Liu A; Osman Y; Takahashi H; Tsukada N; Suzuki N; Nikkuni K; Furukawa T; Koike T; Aizawa Y
J Exp Clin Cancer Res; 1998 Sep; 17(3):251-8. PubMed ID: 9894758
[TBL] [Abstract][Full Text] [Related]
18. [Application of non-steroidal anti-inflammatory drugs to enhance 5-fluorouracil efficacy in experimental systems].
Réti A
Magy Onkol; 2010 Dec; 54(4):377-81. PubMed ID: 21163769
[TBL] [Abstract][Full Text] [Related]
19. Checkpoint inhibition in pediatric hematologic malignancies.
Davis KL; Agarwal AM; Verma AR
Pediatr Hematol Oncol; 2017; 34(6-7):379-394. PubMed ID: 29190182
[TBL] [Abstract][Full Text] [Related]
20. MUC1 in hematological malignancies.
Stroopinsky D; Kufe D; Avigan D
Leuk Lymphoma; 2016 Nov; 57(11):2489-98. PubMed ID: 27347699
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
